Read by QxMD icon Read

second line docetaxel OS

Hideaki Miyake, Takuto Hara, Keita Tamura, Takayuki Sugiyama, Hiroshi Furuse, Seiichiro Ozono, Masato Fujisawa
BACKGROUND: The objective of this study was to compare the efficacies of sequential therapies with novel androgen receptor-axis-targeted (ARAT) agents in patients with docetaxel-naïve metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: This study included 108 consecutive patients with mCRPC who sequentially received abiraterone acetate (AA) and enzalutamide (Enz), in either order, without prior treatment with docetaxel. The combined prostate-specific antigen (PSA) progression-free survival (PFS) was defined as the sum of PFS1 and PFS2, representing PSA PFSs on the first and second ARAT agents, respectively...
December 22, 2016: Clinical Genitourinary Cancer
Solange Peters, Rolf A Stahel, Urania Dafni, Santiago Ponce Aix, Bartomeu Massutí, Oliver Gautschi, Linda Coate, Ana López Martín, Robbert van Heemst, Thierry Berghmans, Peter Meldgaard, Manuel Cobo Dols, Javier Garde Noguera, Alessandra Curioni-Fontecedro, Daniel Rauch, Michael T Mark, Sinead Cuffe, Bonne Biesma, Arjen M J van Henten, Óscar Juan Vidal, Ramón Palmero Sanchez, José Carlos Villa Guzmán, Ricardo Collado Martin, Sergio Peralta, Amelia Insa, Yvonne Summers, István Láng, Anne Horgan, Fortunato Ciardiello, Sander de Hosson, Remge Pieterman, Harry J M Groen, Paul M van den Berg, Christoph C Zielinski, Yojena Chittazhathu Kurian Kuruvilla, Adriana Gasca-Ruchti, Marie Kassapian, Silvia Novello, Valter Torri, Zoi Tsourti, Vanesa Gregorc, Egbert F Smit
INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial...
December 23, 2016: Journal of Thoracic Oncology
Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihide Iwamoto
BACKGROUND: Bone and soft tissue sarcomas (BSTS) are rare malignant tumors. Recently, the combination of gemcitabine and docetaxel (GD) was shown to have activity as second-line setting in BSTS. However, the efficacy as first-line and adjuvant settings and precise profiles of adverse events in Japanese patients are not known yet. In the present study, the feasibility and efficacy of GD in patients with BSTS were investigated. METHODS: Patients with BSTS treated with GD in our institutions were retrospectively analyzed...
December 8, 2016: World Journal of Surgical Oncology
Cesare Gridelli, Antonio Chella, Giuseppe Valmadre, Giacomo Allegrini, Matteo Brighenti, Paolo Bidoli, Antonio Rossi, Paolo Maione, Maria Rita Migliorino, Serena Ricciardi, Filippo DE Marinis
BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients received erlotinib 150 mg/day (arm A; n=36) or docetaxel 75 mg/m(2) on day 1 of each 3-week cycle and erlotinib 150 mg/day on days 2-16 of each cycle (arm B; n=38)...
2016: Anticancer Research
Chee Khoon Lee, Johnathan Man, Sally Lord, Matthew Links, Val Gebski, Tony Mok, James Chih-Hsin Yang
INTRODUCTION: We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. METHODS: Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy...
February 2017: Journal of Thoracic Oncology
Xiaofu Zhu, Yoo-Joung Ko, Scott Berry, Keya Shah, Esther Lee, Kelvin Chan
BACKGROUND: It is unclear which regimen is the most efficacious among the available therapies for advanced gastric cancer in the second-line setting. We performed a network meta-analysis to determine their relative benefits. METHODS: We conducted a systematic review of randomized controlled trials (RCTs) through the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases and American Society of Clinical Oncology abstracts up to June 2014 to identify phase III RCTs on advanced gastric cancer in the second-line setting...
October 8, 2016: Gastric Cancer
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, Rita Axelrod, Douglas Adkins, Shubham Pant, Paul O'Brien, Philip R Debruyne, Kelly S Oliner, Jun Dong, Swami Murugappan
OBJECTIVE: This phase 2 estimation study evaluated docetaxel/cisplatin with/without panitumumab, an anti-epidermal growth factor receptor monoclonal antibody, as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Randomized patients received docetaxel/cisplatin (75mg/m(2) each) with/without panitumumab (9mg/kg) in 21-day cycles. Patients randomized to panitumumab+chemotherapy could continue panitumumab monotherapy after completing six chemotherapy cycles without progression; patients randomized to chemotherapy alone could receive second-line panitumumab after progression...
October 2016: Oral Oncology
Sonya C Tate, Valerie Andre, Nathan Enas, Benjamin Ribba, Ivelina Gueorguieva
PURPOSE: Clinical trials using change in tumour size (CTS) as a primary end-point benefit from earlier evaluation of treatment effect and increased study power over progression-free survival, ultimately resulting in more timely regulatory approvals for cancer patients. In this work, a modelling framework was established to further characterise the relationship between CTS and overall survival (OS) in first-line metastatic breast cancer (mBC). METHODS: Data from three randomised phase III trials designed to evaluate the clinical benefit of gemcitabine combination therapy in mBC patients were collated...
October 2016: European Journal of Cancer
Yi-Hsin Liang, Yu-Yun Shao, Bin-Chi Liao, Ho-Sheng Lee, James Chih-Hsin Yang, Ho-Min Chen, Chun-Ju Chiang, Ann-Lii Cheng, Mei-Shu Lai
AIM: Cytotoxic chemotherapy is the standard first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) without specific gene alterations. This study examined the prescription pattern and the survival outcome of cytotoxic chemotherapy regimens in daily practice in Taiwan. METHODS: We established a population-based cohort of patients diagnosed with advanced NSCLC between 2005 and 2009 using the databases of Taiwan Cancer Registry and National Health Insurance in Taiwan...
2016: Journal of Cancer
Manuel Cobo, Vanesa Gutiérrez, Luis Rodelo, Omar López, María Ruiz, Ana Godoy
Squamous cell carcinoma (SCC) of the lung represents 30% of non-small cell lung cancers (NSCLC). Docetaxel and the EGFR tyrosine kinase inhibitor (TKI), erlotinib, are the only two drugs approved for second-line treatment of advanced SCC. The sensitivity of SCC to TKIs can be explained by EGFR overexpression. Erlotinib demonstrated a significant benefit in terms of overall survival (OS) in successive lines in NSCLC, including squamous histology. The magnitude of this benefit is similar to that of chemotherapy...
April 2016: Medicina Clínica
Ankit Madan, Benjamin S Jones, Rodolfo Bordoni, Mansoor N Saleh, Mary S Jerome, Deborah K Miley, Bradford E Jackson, Francisco Robert
PURPOSE: Given the success of cabazitaxel in patients with prostate cancer who progressed after receiving prior chemotherapy, its preclinical efficacy in various cell lines and possible ability to cross blood-brain barrier, cabazitaxel was hypothesized to increase objective response rate (ORR) in second-line setting in non-small cell lung cancer (NSCLC). METHODS: This was a phase II 2-stage trial in 28 patients using two different treatment schedules (A: 20 mg/m(2) every 3 weeks intravenously and B: 8...
September 2016: Cancer Chemotherapy and Pharmacology
Tobias Engel Ayer Botrel, Otávio Clark, Antônio Carlos Lima Pompeo, Francisco Flávio Horta Bretas, Marcus Vinicius Sadi, Ubirajara Ferreira, Rodolfo Borges Dos Reis
OBJECTIVE: Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC)...
2016: PloS One
L M Smyth, N M Iyengar, M F Chen, S M Popper, S Patil, C Wasserheit-Lieblich, D F Argolo, J C Singh, S Chandarlapaty, S M Sugarman, E A Comen, P R Drullinsky, T A Traina, T Troso-Sandoval, J Baselga, L Norton, C A Hudis, C T Dang
We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer (MBC) treated in the first- and second-line setting. Here, we report results for overall survival (OS) and updated PFS after an additional year of follow-up. Patients with HER2-positive MBC with 0-1 prior treatment were eligible. Treatment consisted of paclitaxel (80 mg/m(2)) weekly, and trastuzumab (loading dose 8 mg/kg → 6 mg/kg) and pertuzumab (loading dose 840 mg → 420 mg) every 3 weeks, all given intravenously...
July 2016: Breast Cancer Research and Treatment
Edoardo Francini, Christopher J Sweeney
UNLABELLED: For >6 yr, docetaxel with prednisone was the only treatment with survival benefits for metastatic castration-resistant prostate cancer (mCRPC). More recently, in clinical practice, abiraterone acetate has been commonly administered prior to docetaxel for the treatment of mCRPC. Our study aimed to review the activity of docetaxel after prior abiraterone. To this end, we analyzed all retrospective reports in the literature describing the overall survival (OS) of mCRPC patients treated with docetaxel after previous abiraterone...
September 2016: European Urology
Alessia Pochesci, Antonio Passaro, Chiara Catania, Cristina Noberasco, Ester Del Signore, Gianluca Spitaleri, Filippo De Marinis
Lung cancer represent the leading cause of cancer related-death worldwide. Although cytotoxic chemotherapy and targeted agents improved survival, the median overall survival for patients with metastatic disease remains poor. Docetaxel is still the corner stone of the second-line treatment, although associated with an unfavourable safety profile. Recent advances in the understanding of cancer immune escape system lead to the development of novel immunotherapies agent that can restore patient's immune response to cancer cells...
April 2016: Recenti Progressi in Medicina
Shinsuke Kanekiyo, Shigeru Takeda, Masao Nakajima, Mitsuo Nishiyama, Masahiro Kitahara, Yoshitaro Shindou, Iida Michihisa, Toshihiro Abe, Shigefumi Yoshino, Shoichi Hazama, Hiroaki Nagano
AIM: In Japan, chemotherapeutic agents that have been approved for the treatment of esophageal cancer include cisplatin, nedaplatin, 5-fluorouracil, vindesine, and docetaxel. The aim of this study was to retrospectively investigate the efficacy and safety of docetaxel and nedaplatin combination chemotherapy for unresectable or recurrent esophageal cancer in an outpatient setting. PATIENTS AND METHODS: In total, 33 patients with recurrent esophageal cancer after initial treatment (esophagectomy, chemotherapy, or chemoradiotherapy) were enrolled...
April 2016: Anticancer Research
Dickran Kazandjian, Daniel L Suzman, Gideon Blumenthal, Sirisha Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur
UNLABELLED: : On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLC after a 3.25-month review timeline. Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy...
May 2016: Oncologist
Omar Abdel-Rahman
BACKGROUND: A meta analysis of the correlation between PD-L1 levels and outcomes of PD-1/PD-L1 inhibitors in advanced non small cell lung cancer (NSCLC) has been performed. METHODS: Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced NSCLC and correlating the outcomes to PD-L1 levels. RESULTS: The search strategy yielded 250 potentially relevant citations from searched databases. After preclusion of ineligible studies, 12 studies were included...
May 2016: Critical Reviews in Oncology/hematology
Wan Ling Tan, Quan-Sing Ng
Squamous cell carcinoma (SCC) of the lung represents about 20-30% of non-small cell lung cancers (NSCLC) and is associated with a poorer prognosis with limited treatment options. Erlotinib is an approved, standard second-line therapy in this setting, besides docetaxel. The LUX-Lung 8 study has shown superior overall survival (OS), progression-free survival (PFS), as well as disease control rates for treatment with afatinib compared to erlotinib in this head-to-head trial in patients with previously treated advanced SCC of the lung, with manageable side effect profile...
February 2016: Translational Lung Cancer Research
Tobias Janowitz, Peter Thuss-Patience, Andrea Marshall, Jung Hun Kang, Claire Connell, Natalie Cook, Janet Dunn, Se Hoon Park, Hugo Ford
BACKGROUND: Second-line chemotherapy treatment of patients with relapsed gastric and oesophageal cancers in comparison with supportive care (SC) alone has been supported by recent phase 3 clinical trials, but a meta-analysis of patient-level data is lacking. METHODS: We searched Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Web of Science for phase 3 clinical trials that compared second-line chemotherapy with SC alone for gastric and oesophageal cancers...
February 16, 2016: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"